Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Cognis CRT-D and Teligen ICD receive FDA approval

Boston Scientific : 14 May, 2008  (New Product)
Boston Scientific has received US FDA approval of its Cognis cardiac resynchronization therapy defibrillator (CRT-D) and Teligen implantable cardioverter defibrillator (ICD).
The devices represent entirely new platforms to treat heart failure and sudden cardiac death and are the result of a multi-year research and development effort to provide physicians enhanced clinical options for their patients.

'Cognis and Teligen are truly breakthrough technologies featuring significant engineering advances,' said Jim Tobin, president and chief executive officer of Boston Scientific. 'These products are testaments to the revitalization of our CRM business and our strong product pipeline. With more than 10 worldwide regulatory approvals since the beginning of the year and several others planned, we are delivering enhanced therapy systems designed to meet clinician needs for safety, reliability and better patient outcomes.'

'When prescribing a high-energy device, I often had to make trade-offs among device size, battery longevity and features,' said Poul-Erik Bloch-Thomson, MD, KAS Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

'The Cognis and Teligen devices eliminate those trade-offs without compromising therapy options.'

The Cognis CRT-D and the Teligen ICD are among the world's smallest and thinnest high-energy devices at 32.5cc and 31.5cc respectively, while less than 10mm thick. Both devices offer features based on substantial engineering advances, including extended battery longevity over previous company devices, self-correcting software and improved programming technology.

Cognis and Teligen are built on entirely new platforms, including device hardware, software and programming interface. Both devices offer a redundant hardware system called SafetyCore, which provides lifesaving shock therapy and basic pacing functionality in the unlikely event of a system error. The products employ digital signal processing and are equipped with increased levels of digital memory, enabling more patient data to be captured and used by clinicians.

Key features of the Cognis CRT-D include:
- SmartDelay - quickly proposes programmable device settings, which enables physicians to tailor individualised pacing therapy for their patients.

- Bi-V Trigger - helps physicians manage heart failure patients with frequent atrial arrhythmias.

- Electronic Repositioning - provides physicians with six configurations for stimulating the left side of the heart even after implant, which may help avoid an additional surgical procedure.

Key features of the Teligen ICD include:
- Thinnest ICD device available in the world - the small size and physiologic shape are designed with patient comfort in mind.

- Quick Convert - provides the ability for patients to receive pacing therapy for ventricular tachycardias.

- Enhanced AV Search algorithm - designed to minimise unnecessary right ventricular pacing. This feature, now with an extendable AV delay out to 400 milliseconds, provides physicians with additional flexibility to tailor device programming for individual patient needs.

Cognis and Teligen are designed to be used with the Latitude Patient Management System. The company intends to offer Latitude support for Cognis and Teligen as soon as possible following FDA approval.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo